Second-line ramucirumab and docetaxel after use of immune checkpoint inhibitors may improve some outcomes for patients with NSCLC. The study was published as a preprint and has not yet been peer reviewed.
Dexamethasone plus wrist and ankle cooling may prevent hand-foot syndrome from doxorubicin in patients with ovarian cancer. The study was published as a preprint and has not yet been peer reviewed.
Advocates who have been calling for reforms in the accelerated approvals process are concerned that Congress may avoid this issue while finalizing a major FDA law.
Results from a randomized trial showed that step therapy for diabetic macular edema with lower-priced bevacizumab followed by pricier aflibercept, when needed, works as well as aflibercept monotherapy.
The first trial comparing panitumumab or bevacizumab plus standard chemotherapy has shown that the former significantly improves survival in left-sided Ras wild type metastatic colorectal cancer.